Pfizer (NYSE:PFE) Stock Price Down 2.3% – Time to Sell?

by · The Cerbat Gem

Pfizer Inc. (NYSE:PFE – Get Free Report) shares fell 2.3% on Tuesday. The company traded as low as $29.89 and last traded at $29.9750. 52,648,660 shares traded hands during mid-day trading, an increase of 33% from the average session volume of 39,723,945 shares. The stock had previously closed at $30.67.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

  • Positive Sentiment: Pfizer beat adjusted earnings expectations in Q3 and raised its 2026 outlook to $62–$64 billion in revenue and $2.95–$3.05 in adjusted EPS. Non-COVID products grew 7% operationally, while launched and acquired products rose 32%, supporting the case that its newer portfolio can offset declines elsewhere. Pfizer Q3 earnings call highlights
  • Positive Sentiment: Guggenheim raised its price target from $31 to $33 and assigned a Buy rating; Scotiabank also raised its target and maintained an outperform rating, signaling improving analyst optimism. Guggenheim rating information
  • Positive Sentiment: Coverage describes Pfizer’s dividend as well-covered and its valuation as modest, which may appeal to income-focused investors. Pfizer stock looks attractive for income investors
  • Neutral Sentiment: Call-option purchases surged well above average, reflecting bullish positioning, though options activity can be speculative and does not establish a sustained outlook.
  • Neutral Sentiment: Pfizer is advancing a Phase 3 study of a monthly obesity treatment. Progress could strengthen its pipeline, but the report provides no trial results yet. Pfizer advances monthly obesity drug study
  • Neutral Sentiment: Goldman Sachs maintained a Hold rating, a counterpoint to the more positive target changes. Goldman Sachs remains a Hold
  • Negative Sentiment: Q3 coverage flagged margin compression. Even with raised guidance and cost reductions, Pfizer must show that new-product growth can translate into durable profitability. Pfizer Q3 deep dive

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Royal Bank Of Canada increased their price objective on shares of Pfizer from $25.00 to $28.00 and gave the stock a “sector perform” rating in a research note on Wednesday. Argus set a $40.00 target price on shares of Pfizer in a research note on Wednesday. Citigroup upped their target price on shares of Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a report on Wednesday. Guggenheim upped their target price on shares of Pfizer from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday. Finally, JPMorgan Chase & Co. increased their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Five analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $29.94.

Get Our Latest Research Report on PFE

Pfizer Price Performance

The firm’s fifty day simple moving average is $28.72 and its 200 day simple moving average is $26.88. The firm has a market cap of $170.47 billion, a P/E ratio of 10.10, a P/E/G ratio of 2.04 and a beta of 0.31. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.96 and a current ratio of 1.42.

Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.13. The firm had revenue of $16.58 billion for the quarter, compared to analysts’ expectations of $15.85 billion. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. The business’s revenue was down .4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.87 earnings per share. As a group, analysts forecast that Pfizer Inc. will post 3.02 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 5.8%. The ex-dividend date is Friday, November 6th. Pfizer’s payout ratio is currently 226.32%.

Hedge Funds Weigh In On Pfizer

Institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC lifted its position in shares of Pfizer by 11.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,132,291 shares of the biopharmaceutical company’s stock valued at $31,840,000 after buying an additional 112,523 shares in the last quarter. Pictet Asset Management Holding SA increased its holdings in Pfizer by 62.8% in the 3rd quarter. Pictet Asset Management Holding SA now owns 4,721,719 shares of the biopharmaceutical company’s stock worth $134,667,000 after acquiring an additional 1,820,944 shares in the last quarter. Leelyn Smith LLC increased its holdings in Pfizer by 3.9% in the 3rd quarter. Leelyn Smith LLC now owns 128,235 shares of the biopharmaceutical company’s stock worth $3,657,000 after acquiring an additional 4,851 shares in the last quarter. Verus Capital Partners LLC increased its holdings in Pfizer by 5.1% in the 3rd quarter. Verus Capital Partners LLC now owns 16,716 shares of the biopharmaceutical company’s stock worth $477,000 after acquiring an additional 805 shares in the last quarter. Finally, W.G. Shaheen & Associates DBA Whitney & Co acquired a new position in Pfizer during the third quarter worth $221,000. Institutional investors own 68.36% of the company’s stock.

About Pfizer

(Get Free Report)

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.

Further Reading